Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome

Table 3

Discussing baseline tumor factors and relation to hormonal therapy interruption in regard to HER2-low.

Parameters		HER2-low		Total	value
		No	Yes
ECOG PS	0	0	2	2	0.16
		0.0%	100.0%	100.0%
	1	64	45	109
		58.7%	41.3%	100.0%
	2	19	20	39
		48.7%	51.3%	100.0%
BMI	Normal	11	12	23	0.56
		47.8%	52.2%	100.0%
	Overweight	23	21	44
		52.3%	47.7%	100.0%
	Obese	49	34	83
		59.0%	41.0%	100.0%
Ki67 level	Low	45	41	86	0.56
		52.3%	47.7%	100.0%
	High	35	25	60
		58.3%	41.7%	100.0%
	NA	3	1	4
		75.0%	25.0%	100.0%
Menopausal status	Premenopause	40	38	78	0.30
		51.3%	48.7%	100.0%
	Postmenopause	43	29	72
		59.7%	40.3%	100.0%
Allred score	≤6	16	8	24	0.22
		66.7%	33.3%	100.0%
	7-8	67	59	126
		53.2%	46.8%	100.0%
Stage at diagnosis	Stage II	2	2	4	0.32
		50.0%	50.0%	100.0%
	Stage III	32	18	50
		64.0%	36.0%	100.0%
	Stage IV	49	47	96
		51.0%	49.0%	100.0%
(Neo) adjuvant chemotherapy	No	67	61	128	0.10
		52.3%	47.7%	100.0%
	Yes	15	6	21
		71.4%	28.6%	100.0%
PR-status	Negative	15	8	23	0.30
		65.2%	34.8%	100.0%
	Positive	68	59	127
		53.5%	46.5%	100.0%
Site of metastasis	Bone-only	18	14	32	0.91
		56.3%	43.8%	100.0%
	Others	65	53	118
		55.1%	44.9%	100.0%
Site of metastasis	Single	33	21	54	0.29
		61.1%	38.9%	100.0%
	Multiple	50	46	96
		52.1%	47.9%	100.0%